Strong full-year 2010 performance and exciting outlook for 2011

Sales and earnings grew strongly in 2010. Overall demand was high in the enzyme
business, and costs were kept under control. For 2011, sales are expected to
grow by 7-10% in DKK, local currency (LCY) and organically. We expect EBIT to
grow by 8-11%, and we expect an EBIT margin of 21-22%, including an investment
of DKK 150 million in additional initiatives in R&D and business-building
activities. Net profit is expected to grow by 8-11%, with investments of around
DKK 1,400 million and free cash flow before acquisitions of DKK 900-1,000
million. The outlook for 2011 excludes any potential impact from the EMD/Merck
Crop BioScience acquisition. 



Read the whole announcement